Global biosimilars market report, 2015 2025 the biosimilar market is projected to be worth usd 32 bi by infomed asia

Home

Development

Manufacturing

Regulatory

OnBiosimilars Blog

Registration

News | November 3, 2015

Global Biosimilars Market Report, 2015-2025 The Biosimilar Market Is Projected To Be Worth USD 32 Billion Worldwide By 2025 Dublin /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" report to their offering. Characterised by increased utility in chronic diseases and capital intensive manufacturing, the global biopharmaceutical market is expanding robustly. As the demand for biologics is increasing continuously, manufacturers are on the lookout for novel strategies that will help them attain maximum returns on investment. Derived from biological elements, biologic medications have transformed the treatment paradigm of life threatening, debilitating diseases. However, such drugs come at staggering prices in the market. Hence, cheaper biological products have become an economic and healthcare requisite. The Global Biosimilars Market, 2015 - 2025' report provides an extensive study of the Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Get the latest articles from Biosimilar Development delivered to your inbox. Email

ď&#x20AC;&#x201A;

rapidly growing biosimilars market. With the blockbuster biologics losing patent protection and biotechnology industry striving to minimize costs, biosimilars are being viewed as viable substitutes to the highly expensive biological medications. The study presents an in-depth review of the developments in established markets and emerging regions, with respect to the market landscape, global and local players, regulatory scenario and emerging opportunities. It provides a detailed analysis of the worldwide pipeline of biosimilars on key parameters such as product categories, indications, biosimilar targets and status of development. The study presents a comprehensive view of key product classes into which biosimilars can be categorized; these include monoclonal antibodies (mAbs), insulin, interferons, G-CSF/ GM-CSF, erythropoietins and others. We have highlighted some of the important aspects specific to these product categories including regulatory guidelines, development challenges, marketed / pipeline biosimilars, sales data (where available) and information on patent expiry of the reference products. The report assesses some of the key drivers that have governed the evolution of biosimilars market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity in the biosimilars market over the next decade, segmented on the basis of geographical clusters and product categories. The study also provides information on some of the most recent activities in this market; amongst others, these include growing collaborations, investment activity and technological advancements. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples of such challenges include manufacturing complexities, heterogeneous regulatory framework, and associated safety and efficacy issues. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

reCAPTCHA

Please upgrade to a supported browser to get a reCAPTCHA challenge. Alternatively if you think you are getting this page in error, please check your connection and reload. ď&#x20AC;&#x2021; internet SIGN ME UP Why is this happening to me?

YOU MAY ALSO LIKE... U.S. Biosimilars Market Worth $11B By 2020 22% CAGR Forecast For Global Biosimilar Industry In New Research Reports T he Global & USA Biosimilar Market Analysis to 2021 research report indicates a high market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry.

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026 Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover, in our updated survey, organisations' outlooks from 2016. T here you see results, trends, opportunities and revenue forecasting.

Global Humira (Adalimumab) Biosimilars Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

The report provides market forecasts for the time period 2020 and 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research. Example Highlights: - The market is driven by the presence of a growing pipeline; during our research, we identified over 600 biosimilar products across various product categories covering mAbs, insulin, interferons amongst others. - Specifically, mAb biosimilars being developed for multiple diseases form a sizeable proportion of the preclinical/clinical development pipeline. In our pipeline, we reviewed around 200 mAb biosimilars. Neupogen, Enbrel and Humira, owing to their staggering revenues, are examples of some of the most popular target reference products. - The emerging pharmaceutical markets of Asia, Latin America and Eastern Europe, with benefits such as lower labour costs, access to regional / domestic markets and, most importantly, relaxed regulatory requirements serve as attractive destinations for biosimilars research and commercialisation. This geographical cluster currently dominates the market with respect to the number of approved products. - In order to exploit the advantages of combined resources and use licensed assets, stakeholders have announced numerous collaborations in the recent past. During our research, we identified around 70 partnerships which have taken place in the biosimilar market over the last few years. - Looking at the ongoing focus, the market is well positioned to achieve a robust growth in the coming decade as the number of patent expiries grows and the legal and regulatory squabbles are sorted out; based on a very comprehensive analysis, we have projected the market to be worth USD 32 billion worldwide by 2025. - Although emerging markets have been on a fast track in the recent past, the desired market uptake in the US and Europe will drive the market to attain its peak potential. Key Topics Covered: 1. Preface 2. Executive Summary Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Clinical Trial Insight Report 2016 - Humira Had Topped US$ 14B Of Sales Globally Research And Markets Research and Marketshas announced the addition of the"Humira Biosimilars Clinical T rial Insight"clinical trials to their offering.

Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight - Research And Markets Research and Markets has announced the addition of the "Herceptin (T rastuzumab) Biosimilar Clinical T rial Insight" clinical trials to their offering.

Global Clinical Insight On 17 Biosimilar Versions Of Remicade (Infliximab) Drug In Clinical Pipeline 2016 - Research And Markets Research and Marketshas announced the addition of the"Remicade (Infliximab) Biosimilar Clinical T rial Insight"clinical trials to their offering.

Biosimilars And Follow-On Biologics' Trends, R&D And Revenue Forecasts 2016-2026 Increasing Need For Cost-Effective Treatment Drives Global Biosimilars Market To Grow At A CAGR Of 55.52% During 2016-2020: MarketResearchReports.biz Global Biosimilars Market Is Expected To Reach $35B By 2020, Finds New Report European Biosimilars Market Opportunity Outlook Report 2015-2020 Biosimilars In Emerging Economies Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put

3. Introduction 4. Biosimilars: Developed Markets 5. Biosimilars: Emerging Markets 6. Global Market Overview 7. Market Dynamics 8. Monoclonal Antibody Biosimilars 9. Insulin Biosimilars 10. Biosimilar Interferons 11. Other Leading Biosimilar Markets 12. Recent Developments 13. Outsourcing of Biosimilars 14. Market Forecast 15. Conclusion 16. Interview Transcripts 17. Appendix 1: Tabulated Data 18. Appendix 2: List of Companies and Organisations -

3S Bio Inc. Abbott AbZ Pharma Accord Healthcare Ltd. Actavis Aequus BioPharma AET Biotech Agila Biotech Alvartis Pharma Alvogen Amega Biotech Amgen Anhui Anke Biotechnology (Group) Co., Ltd Anika Therapeutics ANMAT (Argentina)

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

India And China At A Strategic Advantage In Biosimilar Production Celltrion And Medidata Team Up To Transform Global Clinical Trials For Biosimilars AET BioTech And BioXpress Therapeutics To Co-Develop Biosimilar Adalimumab

Apotex Aprogen Inc. AryoGen ASKA Pharmaceutical Co. Ltd. Aspen Pharmacare Australia Avesthagen Axicorp GmbH AXXO GmbH Barr Pharmaceuticals Baxter International Bayer Healthcare Beacon Pharmaceuticals Ltd. Beijing Four Rings Bio-Pharmaceutical Beijing ShuangLu Pharmaceutical Co., Ltd. Bharat Serums Binex Bio Process Bio Profarma SA Bio Sidus SA Biocad BioCeuticalsArzneimittel AG BioCND Inc. Biocon Biogaran Biogen Idec BioGenomics BioMarin Bionovis Biosano Laboratories Biotechpharma Bioton Bioviz

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

BioXpress Therapeutics BlauFarmaceutica Blue Stream Laboratories BMS Boehringer Ingelheim Boston Oncology, LLC Cadila Pharmaceuticals Cangene Catalent CCL Pharmaceuticals CCM Duopharma Biotech Bhd Cell Therapeutics Cellectis Celltrion Celon Central Drugs Standard Control Organisation Chandra Bhagat Pharma Charles River Laboratories Chemical Company of Malaysia Berhad China Food and Drug Administration CHMP Chong Kun Dang Pharma Chugai Pharmaceuticals CIMAB Cinnagen Cipla CJ Healthcare Claris Lifesciences Clinigene International Pvt. Ltd. CMC Biologics Cobra Biologics COFEPRIS

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

CoGenesys Coherus Biosciences Cook Pharmica Covance CP Guojian Pharmaceutical Co. Ltd CTI BioPharma Curaxys Dabur Daewoong Pharmaceutical Co. Ltd. Daiichi Sankyo Dong A Pharma Dongbao Enterprise Group Ltd. Dr. Reddy's Laboratories Dragon Pharmaceuticals Inc. Egis Pharmaceuticals Eli Lilly Elpen Pharmaceutical Emcure Pharmaceuticals Emergent Biosolutions Epirus Biopharmaceuticals Eurofins Central Global Laboratory Farmabion del Ecuador C.A Farmasa Finox Biotech Fiocruz Fosun Pharmaceutical Fougera Pharmaceuticals Fountain Biopharma Inc. Frontage Laboratories, Inc. Fuji Pharma Fujifilm Kyowa Kirin Biologics Fuso Pharmaceutical Industries

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Gambro Gan& Lee Gedeon Richter Gene Techno Science Genentech Generium GeneScience Pharmaceuticals Genexine Genhelix GenorBiopharma GlaxoSmithKline Goodwin Biotechnology Halozyme Therapeutics Handok Inc. Hangzhou Jiuyuan Gene Engineering Co., Ltd. Hanwha Chemicals Harvest Moon Pharmaceuticals HEC Pharm Henlius Biopharmaceuticals Hetero Drugs Hexal Hikma Pharmaceuticals Hindustan Antibiotics Limited Hospira Hualida Biotech HygeneBiopharm Co. Ltd. iBio Inc. IDDI IDEC Pharmaceuticals Inbiopro INC Research, LLC Incepta Pharmaceuticals Ltd.

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Inno Bio Ventures Sdn Bhd. Innogene Innovent Biologics Insmed Instituto Vital Brazil Intas Pharmaceuticals Intertek InVentiv Health Ipca Laboratories IsuAbxis Itochu Chemical Frontier Corporation Janssen Biotech JCR Pharmaceuticals Johnson & Johnson Julphar Kawsar Biotech Company Kee Pharma Kemwell Biopharma Kern Pharma Kissei Pharmaceuticals KlarvoyantBiogenics Kocak Pharma Kun Wha Pharmaceutical Company La Renon LaboratoriosVarifarma Landsteiner Laboratories LG Lifesciences Liomont LivzonMabpharm Lonza Lupin Mabion

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

mAbxience S.A MannKind Corp Marvel Life Sciences Medicago MEDICE Arzneimittel Putter Meiji Seika Pharma Co., Ltd. Merck & Co Merck KGaA Merieux Alliance MGC Pharma Micro Labs Minapharm Pharmaceuticals Ministry for Health Labour and Welfare (MHLW),Japan Ministry of Food and Drug Safety (MFDS), Korea Mitsubishi Tanabe Pharma MJ BiopharmPvt. Ltd. Mochida Pharmaceutical Momenta Pharma MPI Research Mundipharma International Corporation Mylan Nanogen Biopharmaceuticals Napp Pharmaceuticals Natco Pharma National Health Surveillance Agency (ANVISA) National Institute for Health and Clinical Excellence NCPC Genentech Biotechnology Co. Ltd. Neiss Labs Pvt. Ltd. Neogenica Bioscience Ltd Neuclone Nichi-IkoPharmaceuticals Nippon Kayaku

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Novartis Novo Nordisk NPS Pharmaceuticals Oncobiologics OrygenBiotecnologia Panacea Biotec PanGen Biotech Paras Biopharmaceuticals Parexel Patheon Pfenex Pfizer Pharmaceutical Product Development Inc. Pharmacia PharmaPraxis PlantForm Corporation Pliva PLIVA Probiomed ProFibrix BV Prolong Pharmaceuticals Protalix Biotherapeutics Qilu Pharmaceutical Co., Ltd. Quintiles Raichem Lifesciences Ranbaxy Ratiopharm Reliance GeneMedix Plc Reliance Life Sciences RentschlerBiotechnologie GmbH RG Pharmaceutica RheinMinapharm

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Richter-Helm BioTec GmbH Roche RPG Life Sciences Salix Pharmaceuticals, Ltd. Samarth Life Sciences Samsung Bioepis Sandoz Sanofi Aventis Sanwa Kagaku Kenkyusho Co., Ltd. Schering-Plough Sci Gen Australia Sedico Serum Institute of India SGS Life Science Services Shandong KexingBioproducts Co., Ltd Shanghai Biomabs Pharmaceuticals Co Ltd Shanghai Celgen Bio-Pharmaceutical Shanghai CP Guojian Pharmaceutical Shanghai Fosun Pharmaceutical Shanghai Zhangjiang Biotechnology Limited Company Shantha Biotech Shreya Life Sciences Sicor Biotech Simcere Pharmaceutical Group South Korea's Ministry of Food and Drug Safety Spectrum Pharmaceuticals StadaArneimittel AG STC Biologics Stelis Biopharma Strides Arcolab Limited Symbiosis Synthon Pharmaceuticals

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Taj Pharmaceuticals Takeda Pharmaceuticals TCI Generics Tecpar Teva The Medicines Company Torrent Pharmaceuticals Toyota Tshuho Corp. TTK Healthcare UMN Pharma United Biotech United Therapeutics Corp USFDA USV Limited VHB Life Sciences Ltd. Virchow Biotech Viropro Warner-Lambert Watson Pharmaceuticals WHO WIL Research Wockhardt Wyeth Xiamen Amyotop Biotech Xian Janssen Yoshindo Zenyaku Kogyo Zhejiang Hisun Pharma Zhejiang Huahai Pharmaceutical Co. Ltd. ZhongshanHygeneBiopharm Zuventus Healthcare Ltd. ZydusCadila

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Like what you are reading?

Sign up for our free newsletter Enter Your Email SIGN ME UP By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.

Marketing

Lif e Science Connect

Events & Training

About Us

Request A Media Kit Ad Specifications Article Reprints

BioProcess Online Clinical Leader Drug Discovery Laboratory Network Med Device Online OutsourcedPharma Pharmaceutical Online Life Science Leader Magazine

Outsourced Pharma Events Life Science T raining Institute

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!

Copy r ig h t Â© 1 9 9 6 -2 0 1 6 V er t Ma r k et s, In c. A ll Rig h t s Reser v ed. T er m s of Use. Pr iv a cy St a t em en t .

Convert w ebpages or entire w ebsites to PDF - Use PDFmyURL!